TABLE 6A - NEW DIAGNOSIS CODES
Diagnosis Code	Description	CC	MDC	MS-DRG
A79.82	Anaplasmosis [A. phagocytophilum]	C	18	867, 868, 869
C56.3	Malignant neoplasm of bilateral ovaries	C	13	736, 737, 738, 739, 740, 741, 754, 755, 756
C79.63	Secondary malignant neoplasm of bilateral ovaries	C	13	736, 737, 738, 739, 740, 741, 754, 755, 756
C84.7A	Anaplastic large cell lymphoma, ALK-negative, breast	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(21), 975(21), 976(21)
D55.21	Anemia due to pyruvate kinase deficiency	N	16	811, 812
D55.29	Anemia due to other disorders of glycolytic enzymes	N	16	811, 812
D75.838	Other thrombocytosis	N	16	814, 815, 816
D75.839	Thrombocytosis, unspecified	N	16	814, 815, 816
D89.44	Hereditary alpha tryptasemia	N	16	814, 815, 816
E75.244	Niemann-Pick disease type A/B	N	10	642
F32.A	Depression, unspecified	N	19	881
F78.A1	SYNGAP1-related intellectual disability	N	19	884
F78.A9	Other genetic related intellectual disability	N	19	884
G04.82	Acute flaccid myelitis	M	01	023, 024, 097, 098, 099
G44.86	Cervicogenic headache	N	01	102, 103
G92.00	Immune effector cell-associated neurotoxicity syndrome, grade unspecified	N	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.01	Immune effector cell-associated neurotoxicity syndrome, grade 1	N	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.02	Immune effector cell-associated neurotoxicity syndrome, grade 2	N	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.03	Immune effector cell-associated neurotoxicity syndrome, grade 3	C	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.04	Immune effector cell-associated neurotoxicity syndrome, grade 4	C	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.05	Immune effector cell-associated neurotoxicity syndrome, grade 5	C	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.8	Other toxic encephalopathy	M	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
G92.9	Unspecified toxic encephalopathy	M	01	023, 024, 091, 092, 093
""			15	791(20), 793(20)
I5A	Non-ischemic myocardial injury (non-traumatic)	C	05	314, 315, 316
J12.82	Pneumonia due to coronavirus disease 2019	M	04	193(22), 194(22), 195(22)
""			25	974(21)(22), 975(21)(22), 976(21)(22)	
K22.81	Esophageal polyp	N	06	391, 392
K22.82	Esophagogastric junction polyp	N	06	391, 392
K22.89	Other specified disease of esophagus	N	06	391, 392
K31.A0	Gastric intestinal metaplasia, unspecified	N	06	391, 392
K31.A11	Gastric intestinal metaplasia without dysplasia, involving the antrum	N	06	391, 392
K31.A12	Gastric intestinal metaplasia without dysplasia, involving the body (corpus)	N	06	391, 392
K31.A13	Gastric intestinal metaplasia without dysplasia, involving the fundus	N	06	391, 392
K31.A14	Gastric intestinal metaplasia without dysplasia, involving the cardia	N	06	391, 392
K31.A15	Gastric intestinal metaplasia without dysplasia, involving multiple sites	N	06	391, 392
K31.A19	Gastric intestinal metaplasia without dysplasia, unspecified site	N	06	391, 392
K31.A21	Gastric intestinal metaplasia with low grade dysplasia	N	06	391, 392
K31.A22	Gastric intestinal metaplasia with high grade dysplasia	N	06	391, 392
K31.A29	Gastric intestinal metaplasia with dysplasia, unspecified	N	06	391, 392
L24.A0	Irritant contact dermatitis due to friction or contact with body fluids, unspecified	N	09	606, 607
L24.A1	Irritant contact dermatitis due to saliva	N	09	606, 607
L24.A2	Irritant contact dermatitis due to fecal, urinary or dual incontinence	N	09	606, 607
L24.A9	Irritant contact dermatitis due friction or contact with other specified body fluids	N	09	606, 607
L24.B0	Irritant contact dermatitis related to unspecified stoma or fistula	N	09	606, 607
L24.B1	Irritant contact dermatitis related to digestive stoma or fistula	N	09	606, 607
L24.B2	Irritant contact dermatitis related to respiratory stoma or fistula	N	09	606, 607
L24.B3	Irritant contact dermatitis related to fecal or urinary stoma or fistula	N	09	606, 607
M31.10	Thrombotic microangiopathy, unspecified	M	08	545, 546, 547
M31.11	Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]	M	08	545, 546, 547
M31.19	Other thrombotic microangiopathy	M	08	545, 546, 547
M35.05	Sjogren syndrome with inflammatory arthritis	N	08	545, 546, 547
M35.06	Sjogren syndrome with peripheral nervous system involvement	N	08	545, 546, 547
M35.07	Sjogren syndrome with central nervous system involvement	C	08	545, 546, 547
M35.08	Sjogren syndrome with gastrointestinal involvement	N	08	545, 546, 547
M35.0A	Sjogren syndrome with glomerular disease	N	08	545, 546, 547
M35.0B	Sjogren syndrome with vasculitis	N	08	545, 546, 547
M35.0C	Sjogren syndrome with dental involvement	N	08	545, 546, 547
M35.81	Multisystem inflammatory syndrome	C	08	545(22), 546(22), 547(22)
M35.89	Other specified systemic involvement of connective tissue	C	08	545(22), 546(22), 547(22)	
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	N	08	545, 546, 547
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	N	08	545, 546, 547
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	N	08	545, 546, 547
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	N	08	545, 546, 547
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	N	08	545, 546, 547
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	N	08	545, 546, 547
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	N	08	545, 546, 547
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	N	08	545, 546, 547
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	N	08	545, 546, 547
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	N	08	545, 546, 547
M54.50	Low back pain, unspecified	N	08	551, 552
M54.51	Vertebrogenic low back pain	N	08	551, 552
M54.59	Other low back pain	N	08	551, 552
P00.82	Newborn affected by (positive) maternal group B streptococcus (GBS) colonization	N	15	795(5)
""			23	951
P09.1	Abnormal findings on neonatal screening for inborn errors of metabolism	N	23	947, 948
P09.2	Abnormal findings on neonatal screening for congenital endocrine disease	N	23	947, 948
P09.3	Abnormal findings on neonatal screening for congenital hematologic disorders	N	23	947, 948
P09.4	Abnormal findings on neonatal screening for cystic fibrosis	N	23	947, 948
P09.5	Abnormal findings on neonatal screening for critical congenital heart disease	N	23	947, 948
P09.6	Abnormal findings on neonatal screening for neonatal hearing loss	N	23	947, 948
P09.8	Other abnormal findings on neonatal screening	N	23	947, 948
P09.9	Abnormal findings on neonatal screening, unspecified	N	23	947, 948
R05.1	Acute cough	N	04	204
R05.2	Subacute cough	N	04	204
R05.3	Chronic cough	N	04	204
R05.4	Cough syncope	N	04	204
R05.8	Other specified cough	N	04	204
R05.9	Cough, unspecified	N	04	204
R35.81	Nocturnal polyuria	N	11	695, 696
R35.89	Other polyuria	N	11	695, 696
R45.88	Nonsuicidal self-harm	N	19	883
R63.30	Feeding difficulties, unspecified	N	10	640, 641
R63.31	Pediatric feeding disorder, acute	N	10	640, 641
R63.32	Pediatric feeding disorder, chronic	N	10	640, 641
R63.39	Other feeding difficulties	N	10	640, 641
R79.83	Abnormal findings of blood amino-acid level	N	23	947, 948
S06.A0XA	Traumatic brain compression without herniation, initial encounter	M	PRE	011, 012, 013
""			01	085, 086, 087
""			24	963(14), 964(14), 965(14)
S06.A0XD	Traumatic brain compression without herniation, subsequent encounter	N	23	949, 950
S06.A0XS	Traumatic brain compression without herniation, sequela	N	21	913, 914
S06.A1XA	Traumatic brain compression with herniation, initial encounter	M	PRE	011, 012, 013
""			01	085, 086, 087
""			24	963(14), 964(14), 965(14)
S06.A1XD	Traumatic brain compression with herniation, subsequent encounter	N	23	949, 950
S06.A1XS	Traumatic brain compression with herniation, sequela	N	21	913, 914
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	N	21	917, 918
T40.711D	Poisoning by cannabis, accidental (unintentional), subsequent encounter	N	23	949, 950
T40.711S	Poisoning by cannabis, accidental (unintentional), sequela	N	21	922, 923
T40.712A	Poisoning by cannabis, intentional self-harm, initial encounter	N	21	917, 918
T40.712D	Poisoning by cannabis, intentional self-harm, subsequent encounter	N	23	949, 950
T40.712S	Poisoning by cannabis, intentional self-harm, sequela	N	21	922, 923
T40.713A	Poisoning by cannabis, assault, initial encounter	N	21	917, 918
T40.713D	Poisoning by cannabis, assault, subsequent encounter	N	23	949, 950
T40.713S	Poisoning by cannabis, assault, sequela	N	21	922, 923
T40.714A	Poisoning by cannabis, undetermined, initial encounter	N	21	917, 918
T40.714D	Poisoning by cannabis, undetermined, subsequent encounter	N	23	949, 950
T40.714S	Poisoning by cannabis, undetermined, sequela	N	21	922, 923
T40.715A	Adverse effect of cannabis, initial encounter	N	15	791(20), 793(20)
""			21	917, 918
T40.715D	Adverse effect of cannabis, subsequent encounter	N	23	949, 950
T40.715S	Adverse effect of cannabis, sequela	N	21	922, 923
T40.716A	Underdosing of cannabis, initial encounter	N	23	951
T40.716D	Underdosing of cannabis, subsequent encounter	N	23	949, 950
T40.716S	Underdosing of cannabis, sequela	N	23	949, 950
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	N	21	917, 918
T40.721D	Poisoning by synthetic cannabinoids, accidental (unintentional), subsequent encounter	N	23	949, 950
T40.721S	Poisoning by synthetic cannabinoids, accidental (unintentional), sequela	N	21	922, 923
T40.722A	Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter	N	21	917, 918
T40.722D	Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter	N	23	949, 950
T40.722S	Poisoning by synthetic cannabinoids, intentional self-harm, sequela	N	21	922, 923
T40.723A	Poisoning by synthetic cannabinoids, assault, initial encounter	N	21	917, 918
T40.723D	Poisoning by synthetic cannabinoids, assault, subsequent encounter	N	23	949, 950
T40.723S	Poisoning by synthetic cannabinoids, assault, sequela	N	21	922, 923
T40.724A	Poisoning by synthetic cannabinoids, undetermined, initial encounter	N	21	917, 918
T40.724D	Poisoning by synthetic cannabinoids, undetermined, subsequent encounter	N	23	949, 950
T40.724S	Poisoning by synthetic cannabinoids, undetermined, sequela	N	21	922, 923
T40.725A	Adverse effect of synthetic cannabinoids, initial encounter	N	15	791(20), 793(20)
""			21	917, 918
T40.725D	Adverse effect of synthetic cannabinoids, subsequent encounter	N	23	949, 950
T40.725S	Adverse effect of synthetic cannabinoids, sequela	N	21	922, 923
T40.726A	Underdosing of synthetic cannabinoids, initial encounter	N	23	951
T40.726D	Underdosing of synthetic cannabinoids, subsequent encounter	N	23	949, 950
T40.726S	Underdosing of synthetic cannabinoids, sequela	N	23	949, 950
T80.82XA	Complication of immune effector cellular therapy, initial encounter	N	15	791(20), 793(20)
""			16	814, 815, 816
T80.82XD	Complication of immune effector cellular therapy, subsequent encounter	N	23	949, 950
T80.82XS	Complication of immune effector cellular therapy, sequela	N	21	922, 923
Y35.899A	Legal intervention involving other specified means, unspecified person injured, initial encounter	N		
Y35.899D	Legal intervention involving other specified means, unspecified person injured, subsequent encounter	N		
Y35.899S	Legal intervention involving other specified means, unspecified person injured, sequela	N		
Z11.52	Encounter for screening for COVID-19	N	23	951(22)
Z20.822	Contact with and (suspected) exposure to COVID- 19	N	23	951(22)
Z71.85	Encounter for immunization safety counseling	N	23	951
Z86.16	Personal history of COVID-19	N	23	951(22)
Z91.014	Allergy to mammalian meats	N	23	951
Z91.51	Personal history of suicidal behavior	N	23	951
Z91.52	Personal history of nonsuicidal self-harm	N	23	951
Z92.850	Personal history of Chimeric Antigen Receptor T-cell therapy	N	23	951
Z92.858	Personal history of other cellular therapy	N	23	951
Z92.859	Personal history of cellular therapy, unspecified	N	23	951
Z92.86	Personal history of gene therapy	N	23	951

	Notes:
	(5)-On 'Only Secondary Diagnosis' list
	(14)-Significant trauma body site - head
	(20)-On newborn major problem list
	(21)-In combination with HIV
	(22)-Implemented January 1, 2021